Back to Search
Start Over
Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new?
- Source :
- World journal of gastroenterology. 13(44)
- Publication Year :
- 2007
-
Abstract
- Colorectal cancer constitutes one of the most common malignancies and the second leading cause of death from cancer in the western world representing one million new cases and half a million deaths annually worldwide. The treatment of patients with metastatic colon cancer comprises different regimens of chemotherapeutic compounds (fluoropyrimidines, irinotecan and oxaliplatin) and new targeted therapies. Interestingly, most recent trials that attempt to expose patients to all five-drug classes (fluoropyrimidines, irinotecan, oxaliplatin, bevacizumab and cetuximab) achieve an overall survival well over 2 years. In this review we will focus on the main epidermal growth factor receptor inhibitors demonstrating clinical benefit for colorectal cancer mainly cetuximab, panitumumab, erlotinib and gefitinib. We will also describe briefly the molecular steps that lie beneath them and the different clinical or molecular mechanisms that are reported for resistance and response.
- Subjects :
- Oncology
medicine.medical_specialty
Bevacizumab
Colorectal cancer
Antineoplastic Agents
Gefitinib
Internal medicine
Medicine
Panitumumab
Humans
Topic Highlight
Enzyme Inhibitors
neoplasms
Clinical Trials as Topic
Cetuximab
business.industry
Gastroenterology
Cancer
Antibodies, Monoclonal
General Medicine
Protein-Tyrosine Kinases
medicine.disease
digestive system diseases
Irinotecan
ErbB Receptors
Erlotinib
business
Colorectal Neoplasms
medicine.drug
Subjects
Details
- ISSN :
- 10079327
- Volume :
- 13
- Issue :
- 44
- Database :
- OpenAIRE
- Journal :
- World journal of gastroenterology
- Accession number :
- edsair.doi.dedup.....06b0fb4b70214221ffee8235a58a9f63